Brief Article pubs.acs.org/jmc
Cite This: J. Med. Chem. 2018, 61, 4256−4262
18
F‑Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management
Harikrishna Kommidi,†,∇ Hua Guo,†,∇ Fuad Nurili,‡ Yogindra Vedvyas,† Moonsoo M. Jin,† Timothy D. McClure,§ Behfar Ehdaie,⊥ Haluk B. Sayman,# Oguz Akin,‡ Omer Aras,*,‡ and Richard Ting*,† †
Department of Radiology, Molecular Imaging Innovations Institute, Weill Cornell Medicine, New York, New York 10065, United States ‡ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States § Department of Urology, Weill Cornell Medicine, New York, New York 10065, United States ⊥ Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States # Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Fatih, Istanbul 34303, Turkey S Supporting Information *
ABSTRACT: [18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a
